Lipid nanoparticles deliver one-two punch to shrink resistant oral tumors in preclinical models

Oral squamous cell carcinoma (OSCC) is the most common form of head and neck cancer, and the number of new cases is predicted to rise by 30% in the next decade. Despite decades of cancer research, treating OSCC remains a challenge. The five-year survival rate is approximately 50%, and standard treatments such as ablative surgery and radiation often leave patients with permanent disfigurement or profound, lifelong impairment of essential oral functions such as speaking and swallowing.